Pharmaceuticals
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Potential in BioMedWire Podcast
Quantum BioPharma's co-founder discusses the unmet need in multiple sclerosis treatment with Lucid-MS and the commercial potential of unbuzzd, as the company prepares for a Phase 2 trial.
Oncotelic Therapeutics Maintains $388M JV Valuation Amid Biotech Market Volatility
Oncotelic Therapeutics reported a stable $388 million fair value for its 45% stake in GMP Biotechnology, highlighting its partnership-driven model as a buffer against typical biotech cash burn pressures.
Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Key Clinical Milestones
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions, will participate in a fireside chat at the Jefferies Global Healthcare Conference, highlighting its Phase 3 and Phase 2 programs for major depressive disorder and generalized anxiety disorder.
Optimi Health Welcomes Australia's TGA Framework Update, Expanding Psychedelic Therapy Access
Optimi Health Corp. highlights Australia's updated TGA framework for psilocybin and MDMA, which broadens therapy teams and treatment settings, potentially accelerating adoption of psychedelic-assisted therapy.
Tonix Pharmaceuticals Highlights Persistent Opioid Use in Fibromyalgia Patients Despite Guidelines
A Tonix Pharmaceuticals study reveals that 40% of fibromyalgia patients still receive opioid prescriptions, underscoring a gap between clinical practice and evidence-based recommendations and highlighting the need for non-opioid treatments like TONMYA.
Oncotelic and Sapu Nano to Present Deciparticle Nanomedicine Platform at BIO 2026
Oncotelic Therapeutics and Sapu Nano will showcase their Deciparticle nanomedicine platform at the BIO International Convention 2026, highlighting ultra-small formulations for water-insoluble drugs and AI integration.
Tonix Pharmaceuticals Presents Data on High Economic Burden of Fibromyalgia at ISPOR 2026
Tonix Pharmaceuticals presented real-world data at ISPOR 2026 showing that over 93% of fibromyalgia patients have comorbidities and incur substantial healthcare costs, highlighting the unmet need for effective treatments as the company prepares to launch TONMYA.
Redwood AI and Resilience Biosciences Partner to Accelerate Drug Discovery with AI
Redwood AI Corp. has entered a collaboration with Resilience Biosciences to apply AI-driven computational chemistry for faster, more efficient small-molecule drug development, particularly targeting non-opioid therapeutics.
NanoViricides Proposes NV-387 for Bundibugyo Ebola Outbreak Amid Lack of Approved Treatments
NanoViricides highlights its broad-spectrum antiviral NV-387 as a potential treatment for the Bundibugyo Ebola outbreak in Africa, where no approved vaccines or therapies exist, leveraging its host-targeted mechanism and oral formulation for easier deployment.
Visory Health Promotes Two Executives to C-Suite Amid Rapid Expansion
Visory Health announces promotions of Alexandra Robertson to Chief Growth Officer and Brittney Tierce to Chief Technology Officer, signaling the company's focus on scaling access to affordable prescription drugs.
Tonix Pharmaceuticals Publishes Phase 1 TNX-1500 Data, Paving Way for Kidney Transplant Study
Tonix Pharmaceuticals announced publication of Phase 1 data for TNX-1500, an anti-CD40L monoclonal antibody, showing favorable safety and pharmacodynamics, supporting advancement to a Phase 2 kidney transplant rejection study.
Optimi Health Corp. Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity
Optimi Health Corp. (NASDAQ: OPTH) is highlighted in a Diamond Equity Research report for its role as a commercial-stage psychedelic manufacturer with GMP infrastructure, growing traction in Australia, and potential operating leverage as prescription demand scales.
Carmed Pharmaceuticals Gains CityBiz Feature as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is highlighted in a CityBiz Q&A with founder Mustafa Can as it expands into the U.S. market through platforms like OneLavi and Amazon.
Oncotelic Therapeutics Integrates 28 Million Scientific Abstracts into AI Platform, Signaling Shift in Drug Discovery
Oncotelic Therapeutics has integrated 28 million scientific abstracts into its PDAOAI platform, positioning itself as a key player in the rapidly growing AI drug-discovery market.
SureNano Science Targets Obesity Market with Novel GLP-1 Therapy GEP-44
SureNano Science Ltd. is advancing a differentiated GLP-1-based therapy, GEP-44, aiming to compete in the rapidly growing obesity and metabolic disease market dominated by blockbusters like Ozempic and Wegovy.
Optimi Health Prices $15 Million Public Offering for Nasdaq Uplisting, Aims to Scale Psychedelic Drug Production
Optimi Health Corp. has priced a $15 million public offering as it uplists to the Nasdaq Capital Market, planning to use proceeds to expand production and distribution of its GMP-grade psychedelic drug products for mental health therapies.
Sunshine Biopharma Raises $6 Million in Public Offering to Fund Operations and Drug Development
Sunshine Biopharma Inc. closed a $6 million public offering to support working capital and advance its proprietary drug programs for liver cancer and SARS-related coronaviruses.
Telomir Pharmaceuticals Reports Preclinical Data Showing Telomir-Zn Benefits in Wilson’s Disease Model
Telomir Pharmaceuticals announced peer-reviewed preclinical data demonstrating that Telomir-Zn improved survival and reduced oxidative stress and copper burden in a Wilson’s disease model, expanding the drug’s potential beyond its lead cancer program.
Datavault AI Licenses Technology to Wellgistics Health to Tackle PBM-Driven Drug Pricing Inefficiencies
Datavault AI Inc. has granted an exclusive patent license to Wellgistics Health for its PharmacyChain platform, aiming to reduce prescription drug costs by bypassing traditional pharmacy benefit managers.
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Antiviral Drug Pipeline
NanoViricides closes a $2 million registered direct offering with an institutional investor, providing capital to advance its broad-spectrum antiviral drug NV-387 into Phase II trials.
NanoViricides Highlights Broad-Spectrum Antiviral NV-387 Amid Ebola Outbreak
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool amid the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda.
Lantern Pharma Reports Q1 2026 Results: 47% R&D Cost Reduction and AI Platform Commercialization
Lantern Pharma's Q1 2026 results show a 47% year-over-year reduction in R&D spending, successful FDA milestones, and the launch of withZeta.ai, a commercial AI drug development platform that opens a new revenue stream and extends cash runway into 2027.
SureNano Science's GEP-44 Could Disrupt the Obesity Drug Market with Improved Tolerability
SureNano Science Ltd. is advancing GEP-44, a next-generation GLP-1 therapy with a triple agonist mechanism, aiming to improve upon current obesity treatments by offering better tolerability and potential non-injectable delivery.
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug
NanoViricides announced a $2 million registered direct offering with a single institutional investor, aiming to fund development of its broad-spectrum antiviral NV-387, which targets multiple viruses including COVID-19, influenza, and RSV.
NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase II Trials for MPox in DRC
NanoViricides' quarterly report details progress with NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug designation for measles, highlighting its broad-spectrum antiviral strategy.
Carmed Pharmaceuticals Launches on OneLavi.com as U.S. Expansion Continues
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, expands its U.S. presence by launching select products on OneLavi.com, a curated wellness marketplace.
Dogwood Therapeutics Advances Non-Opioid Pain Pipeline with Phase 2b Data Expected This Fall
Dogwood Therapeutics reported first quarter 2026 financial results, highlighting progress in its non-opioid pain treatments Halneuron and SP16, with key clinical milestones expected in 2026.
CNS Pharmaceuticals Reports Q1 2026 Results, Advances Shift to Acquisition-Driven Growth
CNS Pharmaceuticals reported first-quarter 2026 financial results and outlined its strategic transformation toward an acquisition-driven model focused on neurology and oncology, supported by a $22.5 million private placement.
Kairos Pharma Receives 2026 Healthcare Innovation Award for Drug Resistance Research
Kairos Pharma has been recognized with the 2026 GHP Magazine Healthcare & Pharmaceutical Award as the USA leader in drug resistance development, highlighting its work on cancer therapeutics that address treatment resistance.
SureNano Science Featured in BioMedWire Editorial Highlighting GLP-1 Innovation
SureNano Science Ltd. was featured in a BioMedWire editorial discussing its subsidiary GlucaPharm Inc. and its GEP-44 triple agonist peptide, which aims to improve obesity and diabetes treatment with better tolerability and potential non-injectable delivery.